Moleculera Biosciences was founded by Dr. Madeleine Cunningham and Dr. Craig Shimasaki in response to a need for laboratory evidence supporting an underlying biologic root for seemingly unexplained neuropsychiatric symptoms. The company opened its clinical laboratory in April 2013 specifically to meet the testing needs of physicians treating individuals suffering from perplexing autoimmune neuropsychiatric disorders that are treatable.